A Year of Turbulent Change: China’s Innovative Drugs Reshape the Global Pharmaceutical Landscape
China’s advantages are not only evident in the laboratory but also in the efficiency of “from concept to validation.” On one hand, continuous iterative optimization in mature targets (such as antibody drugs and cell therapies) has endowed numerous projects with clear clinical value. On the other hand, leveraging efficient patient enrollment speeds and early-stage clinical execution capabilities, China can complete proof-of-concept (PoC) faster, transforming scientific hypotheses into evaluable clinical results.
Innovation Engine: How China Becomes the “Supply Side” of High-Quality Pipelines
The concentrated emergence of a large number of high-value, tradable assets in China is not driven by a single factor but results from the synergy of multiple elements. These factors have built a unique ecosystem suited for fast, efficient, and high-level innovation in drug R&D.
- Regulatory Acceleration and Favorable Policies
In recent years, China’s regulatory system has continuously aligned with international standards. Since the National Medical Products Administration (NMPA) joined the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), the review period for Investigational New Drug (IND) applications has been shortened to 60 days, with some pilot projects targeting 30 days, pushing the pace from concept to clinical trials far ahead of Europe and the US. Meanwhile, measures such as the normalization of medical insurance negotiations, accelerated review and approval processes, and standardized clinical trial management have significantly shortened the overall path from R&D to commercialization. Reduced institutional uncertainty provides more stable expectations for innovation.
- Return of Talent and Improved Industrial Foundation
The return of overseas scientific talent and the improvement of domestic training systems have enabled China to fill gaps in R&D capabilities in a relatively short time. Industrial clusters represented by Shanghai Zhangjiang and Suzhou Industrial Park have further enhanced resource allocation efficiency. Additionally, the CRO/CDMO/CRDMO system, exemplified by WuXi AppTec, provides high-quality, cost-effective outsourcing services, allowing Chinese biotechs to advance complex R&D projects with an “asset-light” model.
- Diversified Financing Channels
Reforms such as Chapter 18A of the Hong Kong Stock Exchange have enabled unprofitable biotechs to access listing and financing capabilities, injecting tens of billions of yuan into the industry. In recent years, the improvement of multi-tiered capital markets, including the STAR Market and the Beijing Stock Exchange, has further broadened financing avenues, creating a virtuous cycle between venture capital and new enterprise formation.
- Highly Competitive Ecosystem Fosters Abundant Early-Stage Pipelines
Currently, China has over 5,000 companies in the R&D stage. In a fiercely competitive environment, companies are more inclined to develop best-in-class (BIC) products rather than simple follow-on innovative drugs. This high-quality innovation drive is strongly supported by a clinical ecosystem distinct from that of the West. As shown in Figure 1, oncology clinical trials in China are predominantly initiated by institutions, forming a solid academic and hospital research foundation that enables rapid exploration of early novel concepts. The combined effect of intense competition and a unique clinical structure directly results in a pipeline landscape highly concentrated in early-stage projects (with a prominent share of Phase I and Phase II projects, see Figure 2). The vast number of early-stage assets makes China a global clinical innovation engine and a prime source for Western pharmaceutical companies to screen de-risked projects and supplement their pipelines.
Figure 1. Comparison of Clinical Trial Sponsor Structures in Oncology between China and the US
Figure 2. Comparison of Oncology Drug Pipeline Development Stages between China and the US
- Comparison of China-US Pipelines
From a pipeline structure perspective, China’s R&D is more concentrated on biologics, while the US pipeline is more diversified (see Figure 3). In areas such as ADCs, monoclonal antibodies, and bispecific antibodies, China has a higher total number of ongoing projects than the US (see Figure 4A), whereas the US has a higher number of exclusive projects in core biologic drug classes (see Figure 4B). This key difference indicates that China is a powerful R&D and optimization engine, adept at advancing multiple projects against known targets, while the discovery of entirely new targets and true “from 0 to 1” original innovation remains predominantly led by the US. Therefore, China’s core strength lies in leveraging its efficient clinical ecosystem for specialized iterative optimization of existing concepts, whereas the US remains the primary arena for pioneering entirely new treatment modalities.
Figure 3. Comparison of Oncology Pipeline Share by Treatment Modality between China and the US
Figure 4A. Comparison of Biologic Drug R&D between China and the US: Total Project Count by Biologic Activity Type
Figure 4B. Comparison of Biologic Drug R&D between China and the US: Total Exclusive (n=1) Project Count by Biologic Activity Type
The Next Wave of Breakthroughs: Future Outlook for China’s Oncology Pipeline
From the current pipeline layout, there is significant overlap between China and the US in several frontier directions, particularly in target strategies for next-generation bispecific antibodies, including:
- Immune checkpoint inhibition combined with anti-angiogenesis (e.g., PD-(L)1/VEGF)
- Dual immune checkpoint blockade (e.g., PD-(L)1/CTLA-4)
- T-cell engaging bispecific antibodies (e.g., CLDN18.2/CD3)
PD-1/IL-2 bifunctional biologics are rapidly heating up. In September 2025, Genmab’s $8 billion acquisition of Merus underscored the strategic value of this category. The first randomized controlled trial data is imminent; if efficacy surpasses standard regimens, it will ignite a new wave of immuno-oncology dealmaking.
The CLDN18.2 target is entering a best-in-class race. Astellas’ zolbetuximab (Vyloy), approved by the FDA in 2024, has set a new benchmark for first-line gastric cancer treatment. Chinese companies are accelerating the clinical iteration of next-generation CLDN18.2 products to capture incremental market share in this mature solid tumor target.
Beyond the Dividend: The Next Phase for China’s Innovative Drugs
The intensive investments of the past decade are entering a payoff period, but this does not mean the dividends will continue linearly. China’s innovative drug sector may be transitioning from a phase of dividend release to one of structural reshaping.
The homogenization issues arising from high-density front-end layouts are already becoming apparent. The PD-1 track has validated that when companies concentrate on a few popular targets, even successful R&D can lead to fierce competition and value compression during the commercialization phase. As Zeng Fanyong, Research Director of Ipsos China Healthcare, pointed out, there was a degree of track crowding in the early domestic R&D phase, with numerous companies focusing on the same blockbuster targets. When projects advance to later stages, due to high sunk costs, companies often choose to push forward to market launch, ultimately leading to a rapid accumulation of similar products in the market, intensifying competition, significantly compressing commercial value, and entering a price competition phase accompanied by gradual market consolidation. This structure of “front-end concentration, back-end crowding” may be repeated in more niche areas in the future.
Meanwhile, the industrial division of labor model is still evolving. Not every biotech is suited to transition from R&D to full-chain commercialization. Zeng Fanyong, Research Director of Ipsos China Healthcare, also noted that the full-chain path from R&D to production and commercialization is “long-cycle, capital-intensive, and extremely demanding on resources,” making it unsuitable for most companies. In contrast, a collaboration model based on capability specialization may be a more realistic choice. The trade-off between “doing it all” and “doing it best” will become a critical differentiator for companies.
From a market boundary perspective, going global is becoming a necessity. China is no longer just a single market but a link in the global landscape. Zheng Yongmei, Head of Ipsos China Healthcare, emphasized that companies need to “adopt a global perspective, not just focus on the Chinese market.” Emerging markets such as Southeast Asia, the Middle East, and Latin America still have significant unmet needs, but globalization also entails higher compliance thresholds and a more complex geopolitical environment. Especially in cross-border collaborations, supply chains, and regulatory adaptation, companies must balance opportunities and risks.
Overall, the next phase for China’s innovative drugs is no longer just about competing on “how many products are made,” but about whether they can continuously create real value amid intensifying competition and globalization.
Ipsos, one of the world’s largest market research and consulting firms, provides market research and business consulting services covering the full drug lifecycle, spanning key stages from clinical development to commercial launch across multiple therapeutic areas. Leveraging years of accumulated market data and insights, evaluation models, competitive analysis, and consulting frameworks, Ipsos assists core participants such as pharmaceutical companies and investment institutions in identifying real value, anticipating competitive dynamics in the complex and volatile healthcare market, and supporting the formulation of sustainable growth strategies and key initiatives.
Ipsos Healthcare Business
The Ipsos Healthcare team operates in over 30 countries worldwide, providing insights, evidence, and strategic guidance across the full lifecycle of healthcare products, helping clients combine commercial success with the core goal of improving patients’ quality of life.
In the Chinese market, the team has deep expertise in the pharmaceutical industry for over 20 years, offering professional market research and consulting services spanning from clinical to commercial, hospital to retail channels, and general drugs to specialty drugs. Services include drug potential assessment and sales forecasting, excellent drug launch planning, pricing and access strategy, brand positioning and value proposition development, post-launch brand performance tracking, and hospital and retail channel planning. Leveraging its global network and local experience, the Ipsos Healthcare team continuously supports companies and investment institutions in improving decision-making quality in a complex and changing market environment, achieving long-term, stable growth.